TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Astrana Health ( (ASTH) ) has shared an update.
Astrana Health, Inc. held its 2025 Annual Meeting of Stockholders on June 11, 2025, where the stockholders approved the Amended and Restated 2024 Equity Incentive Plan. This plan, previously approved by the Board, increases the number of shares reserved for issuance by 2,000,000 and extends the plan’s term until March 25, 2035. Additionally, nine directors were elected, Ernst & Young LLP’s appointment as the independent auditor was ratified, and the executive compensation program was approved. These decisions reflect Astrana Health’s strategic efforts to enhance its governance and operational framework, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (ASTH) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Astrana Health stock, see the ASTH Stock Forecast page.
Spark’s Take on ASTH Stock
According to Spark, TipRanks’ AI Analyst, ASTH is a Outperform.
Astrana Health’s strong financial performance and positive earnings call insights drive a favorable outlook, despite technical indicators suggesting bearish momentum. The stock’s high valuation and lack of dividend yield limit its appeal.
To see Spark’s full report on ASTH stock, click here.
More about Astrana Health
Average Trading Volume: 288,841
Technical Sentiment Signal: Sell
Current Market Cap: $1.32B
See more insights into ASTH stock on TipRanks’ Stock Analysis page.